GOLDMAN SACHS GROUP INC - IMMUNOVANT INC ownership

IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 125 filers reported holding IMMUNOVANT INC in Q1 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of IMMUNOVANT INC
ValueSharesWeighting
Q3 2023$19,595,791
+217.6%
510,440
+56.9%
0.00%
+300.0%
Q2 2023$6,169,916
-9.8%
325,246
-26.2%
0.00%0.0%
Q1 2023$6,837,708
+3.8%
440,858
+18.8%
0.00%0.0%
Q4 2022$6,589,652
+1564.1%
371,248
+422.4%
0.00%
Q3 2022$396,000
-58.5%
71,069
-71.0%
0.00%
Q2 2022$955,000
-51.3%
244,952
-31.1%
0.00%
Q1 2022$1,960,000
-21.7%
355,694
+21.0%
0.00%
Q4 2021$2,503,000
-37.3%
293,849
-36.0%
0.00%
-100.0%
Q3 2021$3,989,000
+83.4%
458,973
+123.1%
0.00%
Q2 2021$2,175,000
-87.0%
205,734
-80.3%
0.00%
-100.0%
Q1 2021$16,784,000
-53.8%
1,046,381
+33.0%
0.00%
-55.6%
Q4 2020$36,340,000
+737.5%
786,755
+538.1%
0.01%
+800.0%
Q3 2020$4,339,000
+18.4%
123,301
-18.1%
0.00%0.0%
Q2 2020$3,666,000
+219.1%
150,537
+103.9%
0.00%
Q1 2020$1,149,00073,8420.00%
Other shareholders
IMMUNOVANT INC shareholders Q1 2021
NameSharesValueWeighting ↓
Alpine Global Management, LLC 4,448,017$17,347,0004.39%
Deep Track Capital, LP 9,455,000$36,875,0002.42%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 233$60,000,0000.63%
Octagon Capital Advisors LP 579,061$2,258,0000.60%
Eventide Asset Management 5,372,512$20,953,0000.45%
WITTENBERG INVESTMENT MANAGEMENT, INC. 174,000$679,0000.29%
Frazier Life Sciences Management, L.P. 585,759$2,284,0000.22%
BCK CAPITAL MANAGEMENT LP 54,293$212,0000.16%
PLATINUM INVESTMENT MANAGEMENT LTD 777,590$3,033,0000.12%
Bridgefront Capital, LLC 15,649$61,0000.07%
View complete list of IMMUNOVANT INC shareholders